A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer
PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
120
Participants
Timeline
Start Date
September 30, 2025
Primary Completion Date
December 30, 2026
Study Completion Date
June 30, 2028
Conditions
Cervical Cancer MetastaticCervical Cancer Recurrent
Interventions
DRUG
Famitinib + Camrelizumab
Famitinib + Camrelizumab
All Listed Sponsors
lead
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University